JANE STREET GROUP, LLC - INTRA CELLULAR THERAPIES INC ownership

INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 177 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2020. The put-call ratio across all filers is 0.76 and the average weighting 0.1%.

Quarter-by-quarter ownership
JANE STREET GROUP, LLC ownership history of INTRA CELLULAR THERAPIES INC
ValueSharesWeighting
Q3 2023$984,553
-90.2%
18,901
-88.1%
0.00%
-100.0%
Q2 2023$10,052,113
+72.5%
158,751
+47.5%
0.00%
+50.0%
Q1 2023$5,828,652
+51.4%
107,639
+48.0%
0.00%0.0%
Q4 2022$3,848,660
-12.5%
72,726
-23.0%
0.00%0.0%
Q3 2022$4,396,000
+187.9%
94,480
+253.2%
0.00%
+100.0%
Q2 2022$1,527,000
-82.4%
26,751
-81.1%
0.00%
-66.7%
Q1 2022$8,661,000
-18.1%
141,550
-29.9%
0.00%
-25.0%
Q4 2021$10,571,000
+273.4%
201,965
+166.0%
0.00%
+300.0%
Q3 2021$2,831,000
+17.7%
75,933
+28.8%
0.00%0.0%
Q2 2021$2,406,000
+90.0%
58,957
+58.1%
0.00%
Q1 2021$1,266,000
-73.8%
37,290
-75.5%
0.00%
-100.0%
Q4 2020$4,839,000
-24.6%
152,153
-39.1%
0.00%
-50.0%
Q3 2020$6,414,000
-65.1%
249,957
-65.1%
0.00%
-69.2%
Q2 2020$18,399,000
+2578.2%
716,731
+1503.0%
0.01%
Q1 2020$687,000
-93.9%
44,711
-86.5%
0.00%
-100.0%
Q4 2019$11,323,000
+1703.0%
330,025
+729.6%
0.02%
+700.0%
Q3 2017$628,000
-35.6%
39,780
-33.7%
0.00%
-60.0%
Q1 2017$975,000
+418.6%
59,976
+381.1%
0.01%
+400.0%
Q4 2016$188,000
-68.5%
12,467
-68.1%
0.00%
-66.7%
Q3 2016$596,000
+124.1%
39,100
+690.5%
0.00%
+50.0%
Q4 2015$266,000
-62.3%
4,946
-71.9%
0.00%
-50.0%
Q3 2015$705,000
+281.1%
17,617
+60.2%
0.00%
+100.0%
Q2 2014$185,00011,0000.00%
Other shareholders
INTRA CELLULAR THERAPIES INC shareholders Q3 2020
NameSharesValueWeighting ↓
Sarissa Capital Management LP 675,000$26,203,0007.44%
EcoR1 Capital, LLC 244,950$9,509,0003.75%
Redmile Group, LLC 971,565$37,716,0003.60%
Ghost Tree Capital, LLC 120,000$4,658,0001.34%
SENZAR ASSET MANAGEMENT, LLC 144,624$5,614,304,0001.22%
GREAT POINT PARTNERS LLC 100,000$3,882,0001.11%
BB BIOTECH AG 700,000$27,174,0001.07%
Rhenman & Partners Asset Management AB 115,000$4,464,0000.79%
Lisanti Capital Growth, LLC 12,260$476,0000.72%
Rock Springs Capital Management LP 190,000$7,376,0000.55%
View complete list of INTRA CELLULAR THERAPIES INC shareholders